Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
According to a recent press release a group of more than 40 leaders from academia, industry, philanthropy, and advocacy called today for the Obama Administration, Congress, the National Institutes of Health, and the Department of Defense to increase federal funding for research into imaging technologies for less invasive and more accurate diagnosis of prostate cancer.
Filed under: Diagnosis, Management | Tagged: Diagnosis, imaging, research | 5 Comments »
Reports covered in today’s news commentary include: Prostate cancer diagnosis in men of low socioeconiomic status The commercial launch of a new gene expression test Risks for secondary cancers following different types of radiation therapy Adverse effects of brachytherapy with or without hormone ablation Single-port, robot-assisted laparoscopic radical prostatectomy ARQ 501, a preclinical agent for potential [...]
Filed under: Diagnosis, Drugs in development, Management, Treatment | Tagged: ARQ501, Clarient, gene expression test, low socioeconomic status, radiation therapy, RALP, secondary cancer, single-port, stage | 4 Comments »
In a paper published in the January 1 issue of Cancer Research, it has been suggested that critical distinctions between the hormone receptors of individual prostate cancer patients may explain why some men respond well to hornone therapy and others get only limited benefit. This is not a completely new idea, but authors of this [...]
Filed under: Diagnosis, Drugs in development, Uncategorized | Leave a Comment »
The appropriateness of radical prostatectomy as a form of treatment of prostate cancer in men of 70 years of age and older has been questionned for all sorts of reasons over the years.
Filed under: Management, Treatment | Tagged: Charlson score, Older men, outcomes, radical prostatectomy | Leave a Comment »
In addition to the comentary on outcomes of radical prostatectomy in men of 70 years and older, there are four reports in today’s news, addressing: Garlic as a dietary component that prevents cancer How “knock down” of androgen receptor expression and PCPH expression may potentially impact prostate cancer treatment The clinical impact of discordant post-biopsy and [...]
Filed under: Drugs in development, Management, Treatment | Tagged: discordance, garlic, gene expression, Gleason score, knock down | Leave a Comment »
According to a report in the Washington Post earlier today, based on a letter to the editor published in Nature, researchers at the University of Michigan have shown that gene fusion (a process in which selected DNA sequences fuse together when their chromosomes trade places with each other) can occur in prostate cancer.
Filed under: Diagnosis, Risk | Tagged: gene fusion | Leave a Comment »
[Editorial comment: The following item is written with "tongue in cheek" and is intended to entertain -- although it does have a serious component.] In late 2006 an article was published in the European Heart Journal about cardiovascular risks associated with participating in and watching major sporting events (specifically the soccer “World Cup,” held that [...]
Filed under: Living with Prostate Cancer | Tagged: Browns, Eagles, football, Giants, NFL, Patriots, risk, stress | 2 Comments »
We are horrified to discover that we missed reporting on an important paper presented earlier this year at the annual meeting of the Urologic Research Society.
Filed under: Management, Treatment, Uncategorized | Tagged: second-line therapy | Leave a Comment »
A media release from the University of California at San Diego, issued last Wednesday, positively gushes about the potential of glycopeptide-based cancer “vaccine” immunotherapy for prostate cancer. One would like to think that reputable academic institutions could manage to be slightly less hyperbolic about very early stage clinical research.
Filed under: Drugs in development | Tagged: glycopeptide, immunotherapy, vaccine | 1 Comment »
In a paper just published in the International Journal of Radiation Oncology Biology Physics, the authors sought to evaluate whether patients’ pretreatment serum testosterone (T) levels had any impact on survival after prostate brachytherapy.
Filed under: Management, Treatment | Tagged: ADT, androgen deprivation, baseline, brachytherapy, pretreatment, serum testosterone, survival | Leave a Comment »
In addition to the article on pretreatment testosterone levels and prostate cancer survival (see separate commentary), there are just three other reports in this weekend’s early news:
Filed under: Diagnosis, Drugs in development, Management, Risk, Treatment | Tagged: delta-catenin, Ganoderma lucidum, infection, lingzhi, risk, Trichomonas vaginalis | 1 Comment »
There are a number of rather technical reports in the news today, and we summarize these briefly below, providing the usual links to the abstracts for readers who are interested. In a separate report we have addressed the development of a new nomogram that can be used to predict risk for early disease progression following radical [...]
Filed under: Diagnosis, Drugs in development, Management, Risk, Treatment | Tagged: androgen dependence, epigenetic changes, gene profiling, mechanism, prognosis | Leave a Comment »
An international group has developed and validated a new nomogram designed to predict the probability of early biochemical recurrence after radical prostatectomy (RP). Early identification of patients at risk for recurrence may improve prognosis because early institution of adjuvant therapy may reduce the risk of progression.
Filed under: Management, Treatment | Tagged: early biochemical recurrence, nomogram, post-RP | Leave a Comment »
Representatives of almost all of the major US-based prostate cancer advocacy and support organizations gathered on a conference call earlier today to start a process of greater cooperation between the groups toward shared goals.
Filed under: Uncategorized | 2 Comments »
Here’s a question that comes up over and over again from newly diagnosed patients: “My doctor is suggesting I get hormones in combination with radiation therapy. How long am I likely to be on hormone therapy?”
Filed under: Management, Treatment, Uncategorized | Tagged: hormone therapy, neoadjuvant, outcomes, radiotherapy | 2 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site